Marker Therapeutics (MRKR) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed TScan Therapeutics (TCRX) over the past year, losing 12.0% versus a loss of 88.5%. Over five years, MRKR leads with a -94.0% price change compared with -96.6% for TCRX. Marker Therapeutics is the larger company by market cap ($15.8 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRKR | TCRX |
|---|---|---|
| Share price | $0.95 | $0.2282 |
| Market cap | $15.84M | $15.47M |
| 1-day change | -8.65% | -17.59% |
| YTD return | -36.24% | -77.18% |
| 1-year return | -12.04% | -88.47% |
| 5-year return | -94.03% | -96.62% |
| EPS (TTM) | $-0.42 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.46 | $2.57 |
| 52-week low | $0.84 | $0.224 |
| Distance from 52-week high | -61.38% | -91.12% |
| Analyst consensus | none | hold |
| Avg. price target upside | +728.42% | +338.21% |
| Average volume | 65.70K | 783.59K |
| Shares outstanding | 16.67M | 63.50M |
| Employees | 5 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed TCRX by 76.4 percentage points over the past year.
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
MRKR vs TCRX FAQ
Which is bigger, Marker Therapeutics or TScan Therapeutics?
Marker Therapeutics (MRKR) is larger, with a market capitalization of $15.84M compared with $15.47M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, MRKR or TCRX?
MRKR returned -12.04% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Marker Therapeutics and TScan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Marker Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for TScan Therapeutics.